Challenges in assessing the sunscreen-melanoma association.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 06 2019
Historique:
received: 13 06 2018
revised: 25 10 2018
accepted: 02 11 2018
pubmed: 18 11 2018
medline: 4 9 2019
entrez: 18 11 2018
Statut: ppublish

Résumé

Whether sunscreen use affects melanoma risk has been widely studied with contradictory results. To answer this question we performed a systematic review of all published studies, accounting for sources of heterogeneity and bias. We searched for original articles investigating the sunscreen-melanoma association in humans to February 28, 2018. We then used random-effects meta-analysis to combine estimates of the association, stratified by study design. Stratified meta-analysis and meta-regression were used to identify sources of heterogeneity. We included 21,069 melanoma cases from 28 studies published 1979-2018: 23 case-control (11 hospital-based, 12 population-based), 1 ecological, 3 cohort and 1 randomised controlled trial (RCT). There was marked heterogeneity across study designs and among case-control studies but adjustment for confounding by sun exposure, sunburns and phenotype systematically moved estimates toward decreased melanoma risk among sunscreen users. Ever- vs. never-use of sunscreen was inversely associated with melanoma in hospital-based case-control studies (adjusted odds ratio (OR) = 0.57, 95%confidence interval (CI) 0.37-0.87, p

Identifiants

pubmed: 30447006
doi: 10.1002/ijc.31997
pmc: PMC6451658
mid: NIHMS998860
doi:

Substances chimiques

Sunscreening Agents 0

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2651-2668

Subventions

Organisme : NCI NIH HHS
ID : R21 CA198216
Pays : United States

Informations de copyright

© 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

J Clin Oncol. 2005 Apr 20;23(12):2669-75
pubmed: 15837981
Int J Cancer. 2015 Nov 1;137(9):2227-33
pubmed: 25960371
Evid Based Med. 2016 Aug;21(4):125-7
pubmed: 27339128
Br J Dermatol. 1990 Jan;122(1):43-51
pubmed: 2297503
Cancer Treat Res. 2016;167:17-49
pubmed: 26601858
Int J Cancer. 2000 Jun 15;86(6):879-82
pubmed: 10842205
Pigment Cell Melanoma Res. 2010 Dec;23(6):835-7
pubmed: 20726949
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Br J Cancer. 2011 Dec 6;105 Suppl 2:S66-9
pubmed: 22158324
Melanoma Res. 1998 Aug;8(4):370-8
pubmed: 9764814
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Am J Public Health. 2002 Jul;92(7):1173-7
pubmed: 12084704
Clin Pharmacol Ther. 2011 Jan;89(1):31-3
pubmed: 21170070
Occup Med (Lond). 2017 Oct 1;67(7):569-573
pubmed: 29048595
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Int J Epidemiol. 2008 Jun;37(3):654-67
pubmed: 18276627
Int J Clin Exp Med. 2015 Feb 15;8(2):2378-84
pubmed: 25932176
Ann Intern Med. 2003 Dec 16;139(12):966-78
pubmed: 14678916
Pigment Cell Melanoma Res. 2011 Oct;24(5):879-97
pubmed: 21707960
Circulation. 2015 Nov 10;132(19):1786-94
pubmed: 26438781
J Clin Oncol. 2011 Jan 20;29(3):257-63
pubmed: 21135266
Cancer Detect Prev. 1993;17(6):601-8
pubmed: 8275512
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Eur J Dermatol. 2018 Apr 1;28(2):186-201
pubmed: 29620003
Int J Cancer. 2002 Mar 1;98(1):92-8
pubmed: 11857391
Melanoma Res. 2008 Feb;18(1):1-9
pubmed: 18227701
Neoplasma. 2012;59(3):316-25
pubmed: 22296501
J Clin Epidemiol. 2011 Apr;64(4):380-2
pubmed: 21185693
Photodermatol Photoimmunol Photomed. 2014 Apr-Jun;30(2-3):55-61
pubmed: 24417448
Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1921-2
pubmed: 17932337
Br J Dermatol. 2018 Jan;178(1):140-147
pubmed: 29239489
Int J Cancer. 1988 Sep 15;42(3):319-24
pubmed: 3417359
Int J Cancer. 2000 Dec 1;88(5):838-42
pubmed: 11072258
Cancer Epidemiol. 2016 Oct;44:203-221
pubmed: 27460784
J Natl Cancer Inst. 1986 Mar;76(3):403-14
pubmed: 3456458
Cancer Causes Control. 2008 Sep;19(7):671-9
pubmed: 18307049
J Clin Aesthet Dermatol. 2018 Jan;11(1):35-40
pubmed: 29410729
J Clin Epidemiol. 2012 May;65(5):511-9
pubmed: 22342263
J Invest Dermatol. 2009 Dec;129(12):2766-71
pubmed: 19536149
Epidemiology. 2008 Nov;19(6):766-79
pubmed: 18854702
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Control Clin Trials. 1994 Dec;15(6):512-22
pubmed: 7851112
Int J Cancer. 2000 Jul 1;87(1):145-50
pubmed: 10861466
Br J Dermatol. 2017 Jul;177(1):134-140
pubmed: 28369739
Nat Rev Cancer. 2017 Jul;17(7):393-394
pubmed: 28450704
Melanoma Res. 1995 Feb;5(1):59-65
pubmed: 7734957
Environ Res. 2006 May;101(1):123-31
pubmed: 16290819
J Epidemiol. 2018 Jan 5;28(1):27-33
pubmed: 29176271
Br J Dermatol. 2002 Apr;146 Suppl 61:24-30
pubmed: 11966729
Int J Cancer. 1995 Jun 9;61(6):749-55
pubmed: 7790106
Photodermatol Photoimmunol Photomed. 2017 May;33(3):135-142
pubmed: 28165636
Int J Cancer. 2007 Jul 1;121(1):1-5
pubmed: 17415716
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Stat Med. 2008 Mar 30;27(7):954-70
pubmed: 17676579
Int J Dermatol. 2002 Sep;41(9):557-62
pubmed: 12358823
Z Evid Fortbild Qual Gesundhwes. 2015;109(6):437-44
pubmed: 26474648
Am J Epidemiol. 1995 May 15;141(10):923-33
pubmed: 7741122
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
BMJ. 2004 Jun 19;328(7454):1490
pubmed: 15205295
PLoS One. 2012;7(4):e36348
pubmed: 22558444
Photodermatol Photoimmunol Photomed. 2018 Jan;34(1):13-24
pubmed: 28703311
Melanoma Res. 1999 Apr;9(2):199-205
pubmed: 10380943
Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2583-93
pubmed: 22016471
Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):857-63
pubmed: 9796629
Ann Epidemiol. 2007 Dec;17(12):956-63
pubmed: 18022535
Int J Cancer. 1979 Apr 15;23(4):482-6
pubmed: 437925
Int J Cancer. 1997 Jan 6;70(1):26-31
pubmed: 8985086
J Clin Oncol. 2011 May 10;29(14):e425-6; author reply e427
pubmed: 21464415
Am J Epidemiol. 1985 Oct;122(4):606-19
pubmed: 4025303
Cancer Causes Control. 1996 Mar;7(2):275-83
pubmed: 8740740

Auteurs

Corina S Rueegg (CS)

Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

Jo S Stenehjem (JS)

Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway.

Matthias Egger (M)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Reza Ghiasvand (R)

Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

Eunyoung Cho (E)

Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, RI.
Department of Epidemiology, Brown School of Public Health at Brown University, Providence, RI.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Eiliv Lund (E)

Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.

Elisabete Weiderpass (E)

Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway.
Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Genetic Epidemiology Group, Folkhälsan Research Center, and Faculty of Medicine, Helsinki University, Helsinki, Finland.

Adele C Green (AC)

QIMR Berghofer Medical Research Institute, Brisbane, Australia.
CRUK Manchester Institute, University of Manchester, Manchester, United Kingdom.

Marit B Veierød (MB)

Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH